Generic pharma firm Hikma Pharmaceuticals and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, have signed an exclusive U.S. license agreement to commercialize Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray), an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR).   Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris by ...